Heron Therapeutics (NASDAQ:HRTX) Posts Earnings Results, Misses Expectations By $0.01 EPS

Heron Therapeutics (NASDAQ:HRTX) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.01), FiscalAI reports. The firm had revenue of $35.25 million for the quarter, compared to analyst estimates of $37.50 million. Heron Therapeutics had a negative return on equity of 293.02% and a negative net margin of 22.52%.

Heron Therapeutics Stock Performance

Shares of Heron Therapeutics stock opened at $0.29 on Monday. The firm has a market capitalization of $55.63 million, a PE ratio of -1.54 and a beta of 1.65. The company has a current ratio of 2.49, a quick ratio of 1.51 and a debt-to-equity ratio of 24.35. The firm’s 50 day moving average is $0.32 and its 200 day moving average is $0.67. Heron Therapeutics has a 1 year low of $0.26 and a 1 year high of $1.57.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HRTX. HC Wainwright cut Heron Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 11th. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Wall Street Zen raised Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, October 15th. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $2.00.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting.

The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.

Heron’s commercial activities are primarily focused on the United States, where it works with healthcare providers and institutions to support the use of its products in surgical and oncology settings.